Last reviewed · How we verify

Simvast CR — Competitive Intelligence Brief

Simvast CR (Simvast CR) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: HMG-CoA reductase inhibitor (statin). Area: Cardiovascular.

marketed HMG-CoA reductase inhibitor (statin) HMG-CoA reductase Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Simvast CR (Simvast CR) — Hanmi Pharmaceutical Company Limited. Simvastatin is an HMG-CoA reductase inhibitor that lowers cholesterol by blocking the enzyme responsible for cholesterol synthesis in the liver.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Simvast CR TARGET Simvast CR Hanmi Pharmaceutical Company Limited marketed HMG-CoA reductase inhibitor (statin) HMG-CoA reductase
Crestor rosuvastatin AstraZeneca marketed HMG-CoA reductase inhibitor (statin) HMG-CoA reductase 2003-01-01
Lipitor atorvastatin Pfizer Inc. marketed HMG-CoA reductase inhibitor (statin) HMG-CoA reductase 1996-12-17
FLUVASTATIN SODIUM FLUVASTATIN SODIUM marketed HMG-CoA reductase 1993-01-01
Lescol FLUVASTATIN Novartis marketed HMG-CoA Reductase Inhibitor HMG-CoA reductase 1993-01-01
rosuvastatin 7 days rosuvastatin 7 days Radboud University Medical Center marketed HMG-CoA reductase inhibitor (statin) HMG-CoA reductase
Rosuvastatin (Crestor) Rosuvastatin (Crestor) Minneapolis Heart Institute Foundation marketed HMG-CoA reductase inhibitor (statin) HMG-CoA reductase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

Sponsor landscape (HMG-CoA reductase inhibitor (statin) class)

  1. Organon and Co · 7 drugs in this class
  2. Kuhnil Pharmaceutical Co., Ltd. · 3 drugs in this class
  3. Wenzhou Medical University · 2 drugs in this class
  4. Amgen · 2 drugs in this class
  5. Beijing Tiantan Hospital · 2 drugs in this class
  6. Seoul National University Hospital · 2 drugs in this class
  7. JW Pharmaceutical · 2 drugs in this class
  8. AstraZeneca · 2 drugs in this class
  9. Korea University Anam Hospital · 2 drugs in this class
  10. Gachon University Gil Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Simvast CR — Competitive Intelligence Brief. https://druglandscape.com/ci/simvast-cr. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: